Navigation Links
Gladstone and Izumi Bio in partnership in regenerative medicine and cardiovascular disease
Date:6/16/2008

SAN FRANCISCO, CA June 16, 2008 --- iZumi Bio, Inc. and The J. David Gladstone Institutes, an independent non-profit biomedical research organization, have announced a major research collaboration and licensing agreement to focus on applications for induced pluripotent stem (iPS) cells.

iPS cells are "reprogrammed" adult cells that have similar properties and potential to those of human embryonic stem (ES) cells, yet do not raise the same ethical concerns and can be generated in a patient-specific manner to avoid immune rejection.

"The Gladstone relationship with iZumi Bio combines our work in cardiovascular disease and stem cell science with first-class investors and an experienced management team," said Deepak Srivastava, MD Director of the Gladstone Institute of Cardiovascular Disease. "It's an ideal model for advancing science in a focused, efficient way."

"Gladstone is emerging as a global leader in regenerative medicine and its applications to heart disease," said Thane Kreiner, PhD, iZumi Bio Chief Executive Officer. "This collaboration underscores our commitment and ability to translate the best research in iPS technology to products that address important unmet medical needs."

Elements of the broad partnership include iZumi Bio taking a license to certain Gladstone patents and sponsoring research related to iPS cells and cardiovascular disease. Dr. Srivastava will lead the research and will join iZumi Bio's scientific advisory board.

"We're delighted to add this important new company to our translational research partners," said Gladstone President, Robert W. Mahley, MD, PhD, "We look forward to developing iPS technology into treatments and cures."


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Page: 1

Related biology news :

1. Gladstones Shinya Yamanaka wins prestigious Shaw Prize
2. Smart greenhouse research partnership unveiled
3. National Lung Cancer Partnership and LUNGevity Foundation
4. National Lung Cancer Partnership announces winner of 2007 Career Development Award
5. Springer expands publishing partnership with the Biomedical Engineering Society
6. Plant Physiology and TAIR partnership will provide genetic information to public database
7. KAUST announces academic excellence alliance partnership with Imperial College London
8. Cell Press announces new partnership with the Biophysical Society
9. Citizen Science -- a celebration of partnership between academia and local people
10. Oak Ridge to lead auto supplier R&D partnership
11. GM, Coskata partnership builds on Oklahoma State University biofuels research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 2017 The global biotechnology services outsourcing ... by 2025, according to a new report by ... adaptive of the function of outsourcing certain clinical ... the services outsourced, clinical trial management and contract ... Johnson was the first pharmaceutical company to outsource ...
(Date:1/19/2017)... 2017 BD (Becton, Dickinson and Company) (NYSE: ... will host a live webcast of its Annual Meeting of Shareholders ... The webcast can be accessed from the BD corporate website ... January 31, 2017. ... About BD BD is a global medical technology company ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
Breaking Biology Technology: